EQS-News: RHÖN-KLINIKUM Aktiengesellschaft
/ Key word(s): Half Year Results/Miscellaneous
Corporate News Bad Neustadt a. d. Saale | 10 August 2023
RHÖN-KLINIKUM AG publishes result for first half of 2023 – outlook confirmed
At 45.2 million euros, EBITDA fell short of the previous year’s level (2022: 52.8 million euros). Materials The key figures of the first six months are influenced by two main developments: on the one hand, Now that UKGM and the trade union ver.di on 14 April 2023 reached agreement on a key issues paper for the conclusion of a “job protection and relief collective agreement for UKGM and UKGM Service GmbH”, efforts are now successfully being turned towards overcoming the economic consequences of the strike. This will enable us to seize the opportunities arising from an agreement signed at the end of February 2023 between the Federal State of Hesse, the Universities of Giessen and Marburg, Universitätsklinikum Gießen und Marburg (UKGM) and RHÖN-KLINIKUM AG on UKGM’s entitlement to investment funding. After RHÖN-KLINIKUM AG already in the past had invested over 750 million euros at UKGM from own funds, the next ten years will now see further amounts totalling nearly 850 million euros being invested in healthcare delivery, research and teaching. At the same time, federal state funding totalling roughly 529 million euros coupled with investments of roughly 319 million euros from own funds will enable the two hospitals to keep pace with medical, technical and structural developments in order to continue providing cutting-edge university medical care also in future. Outlook For the current financial year 2023 we continue to expect revenues of 1.5 billion euros within a range of The outlook is further subject to considerable uncertainties in connection with the geopolitical risks brought about by the war in Ukraine and any regulatory measures impacting our remuneration structure in 2023. Full results are published in the Half-Year Report at:
RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 855,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,100 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. www.rhoen-klinikum-ag.com
RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations and Sustainability
10.08.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | RHÖN-KLINIKUM Aktiengesellschaft |
Salzburger Leite 1 | |
97616 Bad Neustadt a.d.Saale | |
Germany | |
Phone: | +49 (0)9771 - 65-0 |
Fax: | +49 (0)9771 - 97 467 |
E-mail: | rka@rhoen-klinikum-ag.com |
Internet: | www.rhoen-klinikum-ag.com |
ISIN: | DE0007042301 |
WKN: | 704230 |
Listed: | Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1700339 |
End of News | EQS News Service |
|
1700339 10.08.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.